Mette Cathrine Ørngreen1, Karen Lindhardt Madsen, Nicolai Preisler, Grete Andersen, John Vissing, Pascal Laforêt. 1. From the Neuromuscular Clinic and Research Unit (M.C.Ø, K.L.M., N.P., G.A., J.V.), Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark; and Centre de Référence de pathologie neuromusculaire Paris-Est (P.L.), Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, France.
Abstract
OBJECTIVE: To assess whether bezafibrate increases fatty acid oxidation (FAO) and lowers heart rate (HR) during exercise in patients with carnitine palmitoyltransferase (CPT) II and very long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies. METHODS: This was a 3-month, randomized, double-blind, crossover study of bezafibrate in patients with CPT II (n = 5) and VLCAD (n = 5) deficiencies. Primary outcome measures were changes in FAO, measured with stable-isotope methodology and indirect calorimetry, and changes in HR during exercise. RESULTS:Bezafibrate lowered low-density lipoprotein, triglyceride, and free fatty acid concentrations; however, there were no changes in palmitate oxidation, FAO, or HR during exercise. CONCLUSION:Bezafibrate does not improve clinical symptoms or FAO during exercise in patients with CPT II and VLCAD deficiencies. These findings indicate that previous in vitro studies suggesting a therapeutic potential for fibrates in disorders of FAO do not translate into clinically meaningful effects in vivo. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that bezafibrate 200 mg 3 times daily is ineffective in improving changes in FAO and HR during exercise in adults with CPT II and VLCAD deficiencies.
RCT Entities:
OBJECTIVE: To assess whether bezafibrate increases fatty acid oxidation (FAO) and lowers heart rate (HR) during exercise in patients with carnitine palmitoyltransferase (CPT) II and very long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies. METHODS: This was a 3-month, randomized, double-blind, crossover study of bezafibrate in patients with CPT II (n = 5) and VLCAD (n = 5) deficiencies. Primary outcome measures were changes in FAO, measured with stable-isotope methodology and indirect calorimetry, and changes in HR during exercise. RESULTS:Bezafibrate lowered low-density lipoprotein, triglyceride, and free fatty acid concentrations; however, there were no changes in palmitate oxidation, FAO, or HR during exercise. CONCLUSION:Bezafibrate does not improve clinical symptoms or FAO during exercise in patients with CPT II and VLCAD deficiencies. These findings indicate that previous in vitro studies suggesting a therapeutic potential for fibrates in disorders of FAO do not translate into clinically meaningful effects in vivo. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that bezafibrate 200 mg 3 times daily is ineffective in improving changes in FAO and HR during exercise in adults with CPT II and VLCAD deficiencies.
Authors: J P Bonnefont; J Bastin; P Laforêt; F Aubey; A Mogenet; S Romano; D Ricquier; S Gobin-Limballe; A Vassault; A Behin; B Eymard; J L Bresson; F Djouadi Journal: Clin Pharmacol Ther Date: 2010-05-26 Impact factor: 6.875
Authors: F Djouadi; F Aubey; D Schlemmer; J P N Ruiter; R J A Wanders; A W Strauss; Jean Bastin Journal: Hum Mol Genet Date: 2005-08-22 Impact factor: 6.150
Authors: F Djouadi; F Aubey; D Schlemmer; S Gobin; P Laforet; R J A Wanders; A W Strauss; J P Bonnefont; J Bastin Journal: J Inherit Metab Dis Date: 2006 Apr-Jun Impact factor: 4.982
Authors: T Lemberger; O Braissant; C Juge-Aubry; H Keller; R Saladin; B Staels; J Auwerx; A G Burger; C A Meier; W Wahli Journal: Ann N Y Acad Sci Date: 1996-12-27 Impact factor: 5.691
Authors: M C Ørngreen; T D Jeppesen; S Tvede Andersen; T Taivassalo; S Hauerslev; N Preisler; R G Haller; G van Hall; J Vissing Journal: Neurology Date: 2009-02-24 Impact factor: 9.910
Authors: Guenter Haemmerle; Tarek Moustafa; Gerald Woelkart; Sabrina Büttner; Albrecht Schmidt; Tineke van de Weijer; Matthijs Hesselink; Doris Jaeger; Petra C Kienesberger; Kathrin Zierler; Renate Schreiber; Thomas Eichmann; Dagmar Kolb; Petra Kotzbeck; Martina Schweiger; Manju Kumari; Sandra Eder; Gabriele Schoiswohl; Nuttaporn Wongsiriroj; Nina M Pollak; Franz P W Radner; Karina Preiss-Landl; Thomas Kolbe; Thomas Rülicke; Burkert Pieske; Michael Trauner; Achim Lass; Robert Zimmermann; Gerald Hoefler; Saverio Cinti; Erin E Kershaw; Patrick Schrauwen; Frank Madeo; Bernd Mayer; Rudolf Zechner Journal: Nat Med Date: 2011-08-21 Impact factor: 87.241
Authors: Loren D M Pena; Sandra C van Calcar; Joyanna Hansen; Mathew J Edick; Cate Walsh Vockley; Nancy Leslie; Cynthia Cameron; Al-Walid Mohsen; Susan A Berry; Georgianne L Arnold; Jerry Vockley Journal: Mol Genet Metab Date: 2016-05-13 Impact factor: 4.797